fructo-oligosaccharide Report issue

Botanical Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Fructooligosaccharides (FOS) also sometimes called oligofructose or oligofructan, are oligosaccharide fructans, used as an alternative sweetener. FOS exhibits sweetness levels between 30 and 50 percent of sugar in commercially prepared syrups. It occurs naturally, and its commercial use emerged in the 1980s in response to demand for healthier and calorie-reduced foods.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

fructooligosaccharide | fructo-oligosaccharide | fructooligosaccharides | fructo-oligosaccharides | idolax | raftilose p95 | short-chain fructo-oligosaccharides

Organizations (43)

Research & Development (43)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Crohn Disease (Phase 1/Phase 2)

Diarrhea (Phase 3)

Enteritis (Phase 3)

Healthy Volunteers (Early Phase 1)

Hyperoxaluria (Phase 1/Phase 2)

Inflammatory Bowel Diseases (Phase 1/Phase 2)

Lymphoma (Phase 1)

Malnutrition (Phase 3)

Neoplasms (Phase 1)

Nephrolithiasis (Phase 1/Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 1)

Osteoporosis (Phase 1/Phase 2)

Pouchitis (Phase 1)

Proctitis (Phase 3)

Steatitis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial Organizations: 43

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue